RxDoctor Payments Data

Linh Dan Nguyen, MD

Obstetrics & Gynecology · Fountain Valley, CANPI 1619932506

Payments from drug & device makers

$5,674in general payments, 2019–2025

Across 208 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Mayne Pharma Commercial LLC$340
  • Coopersurgical, Inc.$261
  • Daiichi Sankyo Inc.$252
  • Astellas Pharma US Inc$247
  • Biogen$234
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,63899%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,674 in reported general payments places this provider in the 90th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$38,542
Medicare patients
169
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$17,874
PremarinEstrogens, Conjugated24$11,581
ProgesteroneProgesterone, Micronized167$8,461
VeozahFezolinetant12$6,172
Estradiol (Twice Weekly)Estradiol46$5,302
Estradiol79$5,208
Np ThyroidThyroid,pork38$1,768
Armour ThyroidThyroid,pork18$1,285
Liothyronine Sodium27$1,161
Estradiol (Once Weekly)Estradiol13$905
Levothyroxine Sodium45$665
ValacyclovirValacyclovir Hcl15$444
Spironolactone21$304
Alendronate Sodium17$269
Clobetasol Propionate19$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$247$24,04527 claims
PfizerPremarin$54$11,58124 claims
Acella Pharmaceuticals, LLCNp Thyroid$16$1,76838 claims
AbbVieArmour Thyroid$1,988$1,28518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →